SCHEMBL16645225

SCHEMBL16645225

CC(C)(O)CC(=O)N1CCN(Cc2ccc3c(c2)CCN(C(=O)OC(C)(C)C)C3)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 1/20 0.56
NR1H2 P55055 1/20 0.50
IDO1 P14902 1/20 0.41
TDO2 P48775 1/20 0.41
IDO2 Q6ZQW0 1/20 0.41
VEGFA P15692 1/20 0.39
EGLN1 Q9GZT9 1/20 0.39
FAAH O00519 1/20 0.39
HSP90AA1 P07900 2/20 0.39
HSP90AB1 P08238 2/20 0.39
GLS O94925 1/20 0.39
MAPK1 P28482 2/20 0.39
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
TP53 P04637 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16634930 0.88 FAAH (0.44) ESR2FAAHHSP90AA1HSP90AB1MAPK1
SCHEMBL31013967 0.87 ESR2 (0.63) ESR2NR1H2IDO1TDO2IDO2
SCHEMBL16645176 0.85 ESR2 (0.55) ESR2NR1H2IDO1TDO2IDO2
SCHEMBL31013856 0.83 NR1H2 (0.62) ESR2NR1H2VEGFAEGLN1FAAH
SCHEMBL16645177 0.82 ESR2 (0.50) ESR2NR1H2IDO1TDO2IDO2
SCHEMBL16634827 0.80 ESR2 (0.52) ESR2NR1H2IDO1TDO2IDO2
SCHEMBL1206797 0.80 HSP90AA1 (0.55) ESR2NR1H2IDO1TDO2IDO2
SCHEMBL30368276 0.80 HSP90AA1 (0.55) ESR2NR1H2IDO1TDO2IDO2
SCHEMBL168265 0.79 ESR2 (0.70) ESR2NR1H2MAPK1NAMPTTMEM97
SCHEMBL14768550 0.79 ESR2 (0.70) ESR2NR1H2MAPK1NAMPTTMEM97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY 2016-08-11 US disclosed
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY 2016-08-11 US disclosed
WO-2015054060-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS NAMPT, NAPRT, NNMT ESR2 4495/4885NR1H2 2307/4885IDO1 952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.